RIGEL PHARMACEUTICALS INC (RIGL:NASDAQ)
$37.39 0.65 (1.7692%)
Analysed RIGEL PHARMACEUTICALS INC (RIGL:NASDAQ) News Sources
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
15-05-2026
yahoo.com
Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story
21-05-2026
yahoo.com
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
21-05-2026
yahoo.com
Pfizer Oncology Partnerships Add Detail To Valuation And Earnings Concerns
24-05-2026
yahoo.com
Rigel to Present at the Jefferies Global Healthcare Conference
27-05-2026
yahoo.com
Knight Therapeutics Launches Tavalisse in Mexico
28-05-2026
yahoo.com
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
16-06-2026
yahoo.com
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
01-07-2026
yahoo.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
07-07-2026
yahoo.com
Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock?
07-07-2026
yahoo.com
What is the current price of RIGEL PHARMACEUTICALS INC (RIGL:NASDAQ)?
The current price of RIGEL PHARMACEUTICALS INC (RIGL:NASDAQ) is $37.39.
RIGEL PHARMACEUTICALS INC (RIGL:NASDAQ) absolute price change since previous trading day?
The absolute price change of RIGEL PHARMACEUTICALS INC (RIGL:NASDAQ) since the previous trading day is $0.65.
RIGEL PHARMACEUTICALS INC (RIGL:NASDAQ) percentage price change since previous trading day?
The percentage price change of RIGEL PHARMACEUTICALS INC (RIGL:NASDAQ) since the previous trading day is 1.7692%.
What is the most recent average sentiment score for RIGEL PHARMACEUTICALS INC (RIGL:NASDAQ)?
The most recent average sentiment score for RIGEL PHARMACEUTICALS INC (RIGL:NASDAQ) is 75 out of 100.
What is the most recent average sentiment for RIGEL PHARMACEUTICALS INC (RIGL:NASDAQ)?
The most recent sentiment for RIGEL PHARMACEUTICALS INC (RIGL:NASDAQ) is .
SEC-8K** Filing Available For RIGEL PHARMACEUTICALS INC (RIGL:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.